Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy
Open Access
- 29 March 2024
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 369, 251-265
Abstract
No abstract availableKeywords
Funding Information
- King's College London
This publication has 70 references indexed in Scilit:
- Evaluation of a DoE based approach for comprehensive modelling of the effect of lipid nanoparticle composition on nucleic acid deliveryBiomaterials, 2023
- The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatoryiScience, 2021
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitorsInternational Immunopharmacology, 2018
- A new cancer immunotherapy via simultaneous DC‐mobilization and DC‐targeted IDO gene silencing using an immune‐stimulatory nanosystemInternational Journal of Cancer, 2018
- Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor siteCancer Immunology, Immunotherapy, 2017
- Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II studyCancer Immunology, Immunotherapy, 2016
- Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell KillingAdvanced Healthcare Materials, 2015
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic TumorsImmunity, 2014
- Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survivalCancer Immunology, Immunotherapy, 2013
- The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activationBiomaterials, 2010